.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
Accenture
Citi
Express Scripts
Fish and Richardson
QuintilesIMS
UBS
Julphar
McKinsey

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,501,893

« Back to Dashboard

Summary for Patent: 4,501,893

Title: 3-{6-[3-Pyrrolidino-1-(4-tolyl)prop-1-enyl]-2-pyridyl}acrylic acid and pharmaceutically acceptable salts thereof
Abstract:This disclosure describes a compound of Formula I ##STR1## (including its pharmaceutically acceptable salts and esters) which has potent antihistamine activity which is substantially free from sedative effects and which has little or no anticholinergic effects.
Inventor(s): Findlay; John W. A. (Chapel Hill, NC), Coker; Geoffrey G. (Bromley, Kent, GB2)
Assignee:
Application Number:06/462,872
Patent Claim Types:
see list of patent claims
Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,501,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8203261Apr 02, 1982

International Patent Family for Patent: 4,501,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria42282► Subscribe
Austria64596► Subscribe
Australia1098283► Subscribe
Australia555083► Subscribe
Bulgaria41821► Subscribe
Bulgaria41822► Subscribe
Bulgaria42003► Subscribe
Bulgaria42004► Subscribe
Bulgaria42005► Subscribe
Bulgaria42185► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Novartis
Healthtrust
Medtronic
Boehringer Ingelheim
Covington
McKinsey
QuintilesIMS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot